A popular swine flu vaccine has been linked to cases of narcolepsy in children.With more than 30 million doses of GlaxoSmithKline’s Pandemrix swine flu vaccine distributed during the H1N1 flu pandemic between 2009 and 2010, new research indicates that the vaccine is putting children at a higher risk for developing narcolepsy.
Pharmaceutical giant GlaxoSmithKline (GSK), which recently pleaded guilty to the largest drug industry scandal in recorded history (http://www.naturalnews.com), has partnered with an India-based pharmaceutical company to develop a six-in-one, single-dose vaccine jab that will deliver vaccine material for polio, diphtheria, tetanus, whooping cough (pertussis), hepatitis B, and Haemophilus influenzae type B specifically to the world’s poorest people living in developing countries.
According to reports, GSK will add the contents of its injectable polio shot to a pentavalent vaccine already being manufactured by Biological E Ltd. that contains the other five vaccines. Together, as part of a 50-50 joint venture, the two companies will manufacture the hexavalent vaccine, which will rival similar combination vaccines for polio currently being developed and administered by rival drug companies in India such as Serum Institute of India Ltd. and Sanofi Pasteur.
A confidential GlaxoSmithKline document recently leaked to the press exposed that within a two-year period, a total of 36 infants died after receiving the 6-in-1 vaccine, Infanrix Hexa.  According to the website Initiative Citoyenne  who reported the news, the 1271 page document revealed that GlaxoSmithKline received a total of 1,742 reports of adverse reactions between October 23, 2009, and October 22, 2011, including 503 serious adverse reactions and 36 deaths. Initiative Citoyenne stated:
It’s not that 14 deaths were recorded by GSK between October 2009 and end in October 2011 as we had originally calculated but 36 (14 from 2010 to 2011 and 22 from 2009 to 2010). In addition to these 36 deaths at least 37 other deaths (sudden death mainly), bringing the total to at least 73 deaths since the launch of the vaccine in 2000, and again, this concerns only the death by sudden death, no further recovery of under-reporting.
Using the figure of 36 deaths over a two-year period, this averages 1.5 deaths per month, which by anyone’s standard is extremely high. Note that only 1 to 10% of adverse reactions to vaccines are actually reported. Therefore, in reality, the problem could potentially be far more serious and the actual number of fatalities much higher.
GlaxoSmithKline employee and whistleblower Blair Hamrick has helped make medical history. Together with his colleague Gregory Thorpe, Blair blew the whistle on criminal practices taking place inside GlaxoSmithKline which have now led to the largest criminal admission and financial settlement in the history of western medicine. GSK is paying a $3 billion fine while pleading guilty to felony crimes. (http://www.naturalnews.com/036416_GlaxoSmithKline_fraud_criminal_char…).
Blair recently joined Mike Adams on the Health Ranger Report for a video interview. In this astonishing interview, Blair describes his firsthand knowledge of the “bribery” of physicians, the push for off-label marketing of drugs for unapproved health conditions, the illegal marketing of drugs to children, how 80 percent of physicians were willing to be “on the take,” and other astonishing details from behind the scenes of the criminally-operated medical mafia known as Big Pharma. Continue reading »
WASHINGTON–Prescription drug giant GlaxoSmithKline will plead guilty and pay $3 billion to resolve federal criminal and civil inquiries arising from the company’s illegal promotion of some of its products, its failure to report safety data and alleged false price reporting as part of the largest health care fraud settlement in U.S. history, the Justice Department announced Monday.
The company agreed to plead guilty to three criminal counts, including two counts of introducing misbranded drugs — Paxil and Wellbutrin — and one count of failing to report safety data about the drug Avandia to the Food and Drug Administration.
GlaxoSmithKline is clearing cash out of eurozone countries on a daily basis to protect itself against a potential banking and liquidity crisis in the region.
Sir Andrew Witty, chief executive of Britain’s biggest drug maker, said that early last year the company had started emptying “tens of millions of pounds” in cash every day out of most eurozone countries into accounts in Britain.
“We don’t leave any cash in most European countries. We sweep any cash we raise during the day out of local banks into banks we think are robust and secure,” he added. “You do your best to actively manage the risk.”
In a shocking display of utter corruption and ignorance, a US Center for Disease Control and Prevention(CDC) advisory committee has officially declared that young boys and men between the ages of 11 and 21 should be vaccinated against human papillomavirus (HPV), the viral infection supposedly linked to causing cervical cancer in women.
Despite the fact that males do not even have a cervix, 12 of the 14 CDC committee members decided that vaccinating boys as young as nine against the virus is still a good idea. And in a separate vote, the majority of the committee members also decided that men as old as 26 should be vaccinated against HPV as well, which encompasses practically all young men.
The decision is founded in the CDC’s belief that Merck & Co.’s Gardasil and GlaxoSmithKline’s (GSK) Cervarix, the two vaccines approved for HPV, also help to prevent genital warts and various types of cancers in males. Such claims, though, have never actually been proven. The studies used as proof are skewed, and all of them were funded by the vaccine manufacturers.
The mainstream media is abuzz with excitement over GlaxoSmithKline’s (GSK) latest offering, a malaria trial vaccine that the company claims can cut the risk of clinical and severe malaria in children by 56 percent and 47 percent, respectively. But what GSK and the media are failing to report are the deadly side effects that may accompany the vaccine.
Unveiled at the Bill & Melinda Gates Foundation‘s recent Malaria Forum conference in Seattle, Wash., the results of the Phase III African study on the malaria vaccine, known as RTS,S, suggest that children who receive three doses of it can derive additional protection against malaria when used in conjunction with other disease control methods. But the findings also show that vaccinated children are at a high risk of serious injury or death as well.
In a rare public humiliation for a British company in the United States, GlaxoSmithKline last night formally agreed to pay $750m (£473m) to settle criminal and civil complaints stemming from a whistleblower’s revelations about a shockingly degraded factory in Puerto Rico.
The case dates back to the 2003 sacking of a quality manager after she found grave shortcomings at a factory in Puerto Rico. The manager, Cheryl Eckard, warned she would retaliate by reporting what she had found to the US authorities.
What followed was an aggressive investigation by the Federal Drugs Administration that involved the seizure of medicines worth $2bn (£1.26bn), the largest such confiscation in history. The plant at Cidra was closed down last year as a consequence of the probe. Drugs affected were Avandia, Paxil – a popular anti-depressant – and Tagamet.
Ms Eckard found problems at the factory ranging from the wrong pills going in the wrong bottles, a contaminated water supply, the use of rented vans for storage and a failure to ensure the sterility of anti-cancer IV drugs.
GSK was charged with knowingly selling contaminated goods.
The whistleblower who flagged up manufacturing problems at GlaxoSmithKline’s (GSK) former plant in Puerto Rico stands to receive about $96m (£60m) after the company finalised a pact with the US Department of Justice.
GSK has agreed to pay $750m and plead guilty to charges related to the manufacture and distribution of adulterated drugs, including the anti-depressant Paxil, at its SB Pharmco Puerto Rico plant between 2001 and 2005.
Cheryl Eckard, a former quality assurance manager at GSK who raised the alarm in 2004, stands to receive about $96m from the federal share, according to the Justice Department.
She filed a suit under a law which entitles whistleblowers to a portion of monetary amounts recovered by the government.
Ms Eckard told reporters in Boston on Tuesday: “This is not something that I ever wanted to do.” But she said she felt it was necessary to blow the whistle because of the implications for patient safety.
Her laywers said she was fired by GSK in 2003 after repeatedly complaining to management about conditions at the plant.